Director/PDMR Shareholding

RNS Number : 8643E

Novacyt S.A.

15 March 2022

 

Novacyt S.A.

("Novacyt" or the "Company")

Director/PDMR Shareholding

Paris, France and Camberley, UK - 15 March 2022 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT ), an international specialist in clinical diagnostics, announces that it has been notified that, on 14 March 2022, the following Director purchased ordinary shares of €1/15 each in the Company (the "Ordinary Shares"):

Director	Title	Number of Ordinary Shares purchased	Average price paid per Ordinary Share	Resultant beneficial holding	% of issued share capital
James McCarthy	Chief Financial Officer	39,670	£2.02	49,670	0.07%

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1.	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	James McCarthy, Chief Financial Officer
2.	Reason for the Notification
a)	Position/status	See 1(a) - classified as a PDMR of the Company
b)	Initial notification/ Amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Novacyt S.A.
b)	LEI	213800BWAC2BF295EG28
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the Financial instrument, type of instrument	ordinary shares of €1/15 each
	Identification code	FR0010397232
b)	Nature of the transaction	Acquisition of Ordinary Shares
c)	Price(s) and volume(s)	Price Volume £2.01 37,310 £2.12 2,360
d)	Aggregated information: · Aggregated volume · Price	Price Volume £2.02 39,670
e)	Date of the transaction	14 March 2022
f)	Place of the transaction	AIM

- End -

Contacts

Novacyt SA

David Allmond, Chief Executive Officer

James McCarthy, Chief Financial Officer

[phone]

SP Angel Corporate Finance LLP (Nominated Adviser and Broker)

Matthew Johnson / Charlie Bouverat (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking)

[phone]

Numis Securities Limited (Joint Broker)

Freddie Barnfield / James Black

[phone]

Allegra Finance (French Listing Sponsor)

Rémi Durgetto / Yannick Petit

[phone]

[e-mail] / [e-mail]

FTI Consulting (International)

Victoria Foster Mitchell / Alex Shaw

[phone]

[e-mail] / [e-mail] / [e-mail]  

FTI Consulting (France)

Arnaud de Cheffontaines

[phone]

[e-mail]  

About Novacyt Group

The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.

For more information, please refer to the website: www.novacyt.com  

 

END

 

 

DSHGPUWGWUPPGCA